Cryosite Limited (ASX:CTE – Get Free Report) insider Mark Kerr sold 154,494 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of A$1.05 ($0.70), for a total transaction of A$162,218.70 ($108,145.80).
Mark Kerr also recently made the following trade(s):
- On Tuesday, April 23rd, Mark Kerr acquired 1,000,000 shares of Cryosite stock. The shares were bought at an average cost of A$0.83 ($0.55) per share, with a total value of A$830,000.00 ($553,333.33).
Cryosite Stock Performance
The company has a debt-to-equity ratio of 87.26, a current ratio of 2.32 and a quick ratio of 1.76.
Cryosite Company Profile
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.
Featured Stories
- Five stocks we like better than Cryosite
- ETF Screener: Uses and Step-by-Step Guide
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 6/24 – 6/28
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Cryosite Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryosite and related companies with MarketBeat.com's FREE daily email newsletter.
